In Situ Engineering of Tumor Cells as Self‐Sustaining cDC1 Programming Factories for Effective Cancer Immunotherapy

Conventional type 1 dendritic cells (cDC1s) play a crucial role in initiating and regulating antitumor immunity. However, the insufficient infiltration and dysfunctional state of these cells within the tumor microenvironment hinder antitumor immune response. A tumor-derived extracellular vesicle (EV), termed AS16-EL@MPLA/p-FX, is designed to engineer tumor cells into cDC1 programming factories. The EV lumen carries a plasmid encoding XCL1 and FLT3L. Leveraging the prolonged circulation time and homotypic targeting properties of tumor-derived EV, AS16-EL@MPLA/p-FX demonstrates enhanced tumor-selective accumulation and efficient cellular internalization. Following uptake, tumor cells are reprogrammed into in situ cytokine factories that continuously secrete XCL1 and FLT3L, which effectively recruit and differentiate cDC1s within the tumor microenvironment. Simultaneously, MPLA embedded in the EV membrane is released locally and activates the newly accumulated cDC1s through the TLR4 pathway. Furthermore, an AS16 peptide is tethered to the EV surface via a matrix metalloproteinase-2-cleavable linker. The enzymatic release of AS16 disrupts the VEGF-NRP1 interaction, preventing cDC1 exhaustion. The engineered EV, AS16-EL@MPLA/p-FX, exhibited remarkable tumor-targeting capabilities, promoting the recruitment, differentiation, and activation of cDC1s. This innovative approach not only significantly inhibited tumor growth but also triggered a robust immune memory response, safeguarding against tumor metastasis and recurrence.